Get started
Author

Kimberly Duff

Health-related quality of life of children with primary immunodeficiency disease: a comparison study
2004 · Kathy Zebracki, Tonya M. Palermo, et al. · Annals of Allergy Asthma & Immunology · 52
Hyaluronidase‐facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE‐CIDP 1 randomized controlled trial
2023 · Vera Bril, Robert D. M. Hadden, et al. · Journal of the Peripheral Nervous System · 47
PDF
Subcutaneous Immunoglobulin-G Replacement Therapy with Preparations Currently Available in the United States for Intravenous or Intramuscular Use: Reasons and Regimens
2005 · Akhilesh Chouksey, Kimberly Duff, et al. · Allergy Asthma and Clinical Immunology · 20
PDF
Long‐term safety and tolerability of hyaluronidase‐facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE‐CIDP 3 trial
2024 · Robert D. M. Hadden, Henning Andersen, et al. · Journal of the Peripheral Nervous System · 16
You Can Make a Difference in the Administration of Intravenous Immunoglobulin Therapy
2006 · Kimberly Duff · Journal of Infusion Nursing · 7
Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants
2024 · Zhaoyang Li, Andras Nagy, et al. · Journal of Clinical Immunology · 4
Practical Considerations for Self-Administration of Subcutaneous Immunoglobulin G Utilizing Recombinant Human Hyaluronidase, an Advanced Method of Subcutaneous Administration
2016 · Linda K. Miars, Michelle Tran, et al. · Journal of Infusion Nursing · 4
P255 Real-world pediatric experience with hyaluronidase-facilitated subcutaneous immunoglobulin (IGHY) infusion parameters
2016 · P. Gruenemeier, C. Ernst, et al. · Annals of Allergy Asthma & Immunology · 4
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults
2023 · Andras Nagy, Kimberly Duff, et al. · Journal of Clinical Immunology · 3
PDF
P259 Retrospective review of needle length and clinical considerations during hyaluronidase-facilitated subcutaneous administration of immunoglobulin (IGHY)
2016 · P. Gruenemeier, C. Ernst, et al. · Annals of Allergy Asthma & Immunology · 3
IgG replacement by the subcutaneous route using preparations licensed in the USA for administration by other routes
2004 · K.A. Duff, S. Roy, et al. · Journal of Allergy and Clinical Immunology · 3
The Results of ADVANCE ‐ CIDP IVIG Trial: Intravenous Immunoglobulin 10% Therapy With GAMMAGARD LIQUID /Kiovig for Treatment of Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
2025 · Mamatha Pasnoor, Colin Anderson‐Smits, et al. · European Journal of Neurology · 2
PDF
Efficacy and safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in US pediatric patients with primary immunodeficiency disease
2023 · Niraj Patel, Jolan Walter, et al. · Clinical Immunology · 2
Facilitated subcutaneous immunoglobulin 10% at a target dose of 0.4 g/kg/infusion is well tolerated with accelerated or no dose ramp-up in healthy participants
2023 · Zhaoyang Li, Andras Nagy, et al. · Clinical Immunology · 1
Rationale and Design of a Phase 3b Study of the Long-Term Tolerability and Safety of HyQvia in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): ADVANCE-CIDP 3 (4331)
2020 · Shabbir Hasan, Kimberly Duff, et al. · Neurology · 1
Analysis of Local Treatment-emergent Adverse Events in Patients With CIDP Treated With fSCIG During the ADVANCE-CIDP1 and Long-term ADVANCE-CIDP3 Trials (P7-9.001)
2026 · Ade Ajibade, Faisal Riaz, et al. · Neurology
Individualized Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administration in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Nurse’s Role
2025 · Kim Duff, Arianna Soresini, et al. · Journal of Infusion Nursing
Tolerability and safety of facilitated subcutaneous immunoglobulin 20% in healthy adults: a phase 1 open-label study
2023 · Andras Nagy, Noor Khaskhely, et al. · Clinical Immunology
Patient-centric design of a multivial access device using modular innovation principles to further improve the facilitated subcutaneous immunoglobulin administration experience
2023 · Kimberly Duff, Stefan Holzner, et al. · Clinical Immunology
Feasibility Assessment of Facilitated Subcutaneous Immunoglobulin 1.0 G/Kg with Abbreviated Dose Ramp-Up and without Ramp-Up: A Phase 1 Tolerability and Safety Study in Healthy Adults (P6-4.003)
2023 · Zhaoyang Li, Andras Nagy, et al. · Neurology
Phase 3 Study of Facilitated Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Interim Analysis of Immunogenicity (4194)
2021 · Shabbir Hasan, Hakan Ay, et al. · Neurology
Retrospective Review of Needle Length and Other Considerations During Hyaluronidase-facilitated Subcutaneous Administration of Immunoglobulin (fscig)
2016 · Kimberly Duff
Real-world Pediatric Experience With of Hyaluronidase-facilitated Subcutaneous Immunoglobulin (fscig) Infusion Parameters
2016 · Kimberly Duff
Subcutaneous IgG for antibody deficiency: Reasons and rationales
2005 · K. Duff, N. Wasserbauer, et al. · Journal of Allergy and Clinical Immunology
PDF
Works count: 24
Citation count: 169
H-index: 5
I10-index: 4
Year
Topic
Type